Oslo, Norway, 30 May 2024 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The company is delighted to introduce the newest member of our board at AdjuTec, Espen Franzon Amundsen!
Espen brings a wealth of experience to our team, having recently joined Kistefos AS in 2024. Prior to his role at Kistefos, Espen made significant contributions in the Investment Banking Division at ABG Sundal Collier.
Espen holds a Master of Science degree in Economics and Business Administration with a major in Finance from the esteemed Norwegian School of Economics. His expertise and insights are invaluable assets as we continue to drive innovation and growth at AdjuTec.
Please join us in extending a warm welcome to Espen as he embarks on this exciting journey with us!
Espen brings a wealth of experience to our team, having recently joined Kistefos AS in 2024. Prior to his role at Kistefos, Espen made significant contributions in the Investment Banking Division at ABG Sundal Collier.
Espen holds a Master of Science degree in Economics and Business Administration with a major in Finance from the esteemed Norwegian School of Economics. His expertise and insights are invaluable assets as we continue to drive innovation and growth at AdjuTec.
Please join us in extending a warm welcome to Espen as he embarks on this exciting journey with us!
About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.
About AdjuTec Pharma
AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com
Follow us on LinkedIn and Twitter